216 185

Cited 38 times in

High-dose Versus Standard-dose Radiotherapy with Concurrent Chemotherapy in Stages II-III Esophageal Cancer

DC FieldValueLanguage
dc.contributor.author금웅섭-
dc.contributor.author서양권-
dc.contributor.author이익재-
dc.contributor.author이창걸-
dc.contributor.author차지혜-
dc.date.accessioned2015-01-06T17:02:13Z-
dc.date.available2015-01-06T17:02:13Z-
dc.date.issued2014-
dc.identifier.issn0368-2811-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99240-
dc.description.abstractOBJECTIVE: In this study, we investigated the effects of radiotherapy ≥60 Gy in the setting of concurrent chemo-radiotherapy for treating patients with Stages II-III esophageal cancer. METHODS:A total of 126 patients treated with 5-fluorouracilbased concurrent chemo-radiotherapy between January 1998 and February 2008 were retrospectively reviewed. Among these patients, 49 received a total radiation dose of <60 Gy (standard-dose group), while 77 received a total radiation dose of ≥60 Gy (high-dose group). The median doses in the standard- and high-dose groups were 54 Gy (range, 45-59.4 Gy) and 63 Gy (range, 60-81 Gy), respectively. RESULTS:The high-dose group showed significantly improved locoregional control (2-year locoregional control rate, 69 versus 32%, P < 0.01) and progression-free survival (2-year progression-free survival, 47 versus 20%, P = 0.01) than the standard-dose group. Median overall survival in the high- and the standard-dose groups was 28 and 18 months, respectively (P = 0.26). In multivariate analysis, 60 Gy or higher radiotherapy was a significant prognostic factor for improved locoregional control, progression-free survival and overall survival. No significant differences were found in frequencies of late radiation pneumonitis, post-treatment esophageal stricture or treatment-related mortality between the two groups. CONCLUSIONS:High-dose radiotherapy of 60 Gy or higher with concurrent chemotherapy improved locoregional control and progression-free survival without a significant increase of in treatment-related toxicity in patients with Stages II-III esophageal cancer. Our study could provide the basis for future randomized clinical trials.-
dc.description.statementOfResponsibilityopen-
dc.format.extent534~540-
dc.relation.isPartOfJAPANESE JOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHChemoradiotherapy*/adverse effects-
dc.subject.MESHChemoradiotherapy*/methods-
dc.subject.MESHCisplatin/administration & dosage-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDose-Response Relationship, Radiation-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHEsophageal Neoplasms/drug therapy*-
dc.subject.MESHEsophageal Neoplasms/pathology-
dc.subject.MESHEsophageal Neoplasms/radiotherapy*-
dc.subject.MESHEsophageal Stenosis/etiology-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHIncidence-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPlatinum Compounds/administration & dosage-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiation Pneumonitis/etiology-
dc.subject.MESHRadiotherapy Dosage-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Factors-
dc.subject.MESHTaxoids/administration & dosage-
dc.subject.MESHTreatment Failure-
dc.subject.MESHTreatment Outcome-
dc.titleHigh-dose Versus Standard-dose Radiotherapy with Concurrent Chemotherapy in Stages II-III Esophageal Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorYang-Gun Suh-
dc.contributor.googleauthorIk Jae Lee-
dc.contributor.googleauthorWong Sub Koom-
dc.contributor.googleauthorJihye Cha-
dc.contributor.googleauthorJong Young Lee-
dc.contributor.googleauthorSoo Kon Kim-
dc.contributor.googleauthorChang Geol Lee-
dc.identifier.doi10.1093/jjco/hyu047-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00273-
dc.contributor.localIdA01891-
dc.contributor.localIdA03055-
dc.contributor.localIdA03240-
dc.contributor.localIdA04009-
dc.relation.journalcodeJ01207-
dc.identifier.eissn1465-3621-
dc.identifier.pmid24771865-
dc.subject.keywordchemotherapy-
dc.subject.keywordconcurrent chemo-radiotherapy-
dc.subject.keywordesophageal cancer-
dc.subject.keywordradiotherapy-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.alternativeNameSuh, Yang Gun-
dc.contributor.alternativeNameLee, Ik Jae-
dc.contributor.alternativeNameLee, Chang Geol-
dc.contributor.alternativeNameCha, Ji Hye-
dc.contributor.affiliatedAuthorKoom, Woong Sub-
dc.contributor.affiliatedAuthorSuh, Yang Gun-
dc.contributor.affiliatedAuthorLee, Ik Jae-
dc.contributor.affiliatedAuthorLee, Chang Geol-
dc.contributor.affiliatedAuthorCha, Ji Hye-
dc.citation.volume44-
dc.citation.number6-
dc.citation.startPage534-
dc.citation.endPage540-
dc.identifier.bibliographicCitationJAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.44(6) : 534-540, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.